Maintenance Venetoclax in AML Fit Patients

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Acute Myeloid Leukaemia (AML)

In brief

this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.

Key facts

Study ID

NCT07244367

Run by

Sohag University

People needed

80

Starts

2025-09-01

Expected to finish

2027-09-01

Last updated by the study team

2025-11-24

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age : 18 - 60 years . Patients who are not eligible for immediate bone marrow transplantation. Newly diagnosed AML patients who attained CR after 1st line. Refractory / recurrant AML patients who attained CR after 2nd line .

You may not qualify if…

• Patients not on CR . Age : younger than 18 or older than 60 . Patients not eligible for bone marrow transplation

Where it is running

• Sohag university hospital — Sohag, Egypt (enrolling)
• Sohag university — Sohag, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.